MONTREAL, Aug. 5, 2014 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo
International plc (NASDAQ: ENDP) (TSX: ENL), announced today the launch of
Travelan®, a unique over-the-counter product to help reduce the risk of
Travelan® is clinically proven to provide protection against the main cause
of travellers' diarrhea in 90% of consumers who use it(1). Travelan® is a
convenient option for all those travelling to at-risk regions such as Central
and South America, Mexico, Africa, the Middle East and Asia. It does not
require a prescription, and is not associated with any significant side
It is estimated that there are over 5 million trips made by Canadians to
at-risk regions every year(2). One-in-three Canadian vacationers have
experienced, or have travelled with someone who has experienced, travellers'
diarrhea(3). Sources of Enterotoxigenic Escherichia Coli (ETEC) bacteria,
which cause the majority of cases of travellers' diarrhea(4), can include
poorly cooked meat, contaminated raw vegetables or unpasteurized dairy
products. Given that no food group can be regarded as "safe"(4), research
demonstrates that three-quarters of Canadians have indicated that they would
take a preventive for travellers' diarrhea(3).
"We are pleased to announce the launch of Travelan® in Canada," said Mark
Beaudet, President of Paladin Labs Inc. "This option responds to the clear
market need for a clinically proven, accessible option to help reduce the risk
of travellers' diarrhea."
Paladin obtained the exclusive rights to market and sell Travelan(® )in
Canada, Latin America (including Brazil and Mexico) and Sub-Saharan Africa
(including South Africa) from Immuron Ltd (ASX:IMC) in November 2011.
Travelan(®) is a natural product which is specifically designed to reduce the
risk of infection by ETEC, the most common cause of travellers' diarrhea. In
clinical trials, Travelan(®) showed efficacy of up to 90% in protecting
against infection with the type of E.Coli that causes travellers' diarrhea. In
addition, trials showed a significant reduction in abdominal cramps and
stomach pain compared to those who did not receive Travelan(®). There were no
reported treatment-related side effects in the clinical trials.
For more information, please visit www.travelancanada.ca
Suggested retail price: $29.99-39.99 (pack of 30 tablets).
Available on pharmacy shelves.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products for the Canadian market. Paladin has a focused
marketing and sales organization that has helped it evolve into one of
Canada's leading specialty pharmaceutical companies. Paladin is an operating
company of Endo International plc (NASDAQ: ENDP) (TSX: ENL), a global
specialty healthcare company focused on improving patients' lives while
creating shareholder value. Learn more at www.endo.com.
(1 )Travelan Product Packaging, 2013.
(2 )Statistics Canada, International Travel 2010, Catalogue no. 66-201-X.
(3 )Leger Marketing, State of Vacation: Canadians Perspectives on Travellers'
Diarrhea, October 2011.
(4 )Public Health Agency of Canada, Canada Communicable Disease Report:
Statement on Travellers' Diarrhea, 15 March 2001.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and Canadian securities
legislation. Statements including words such as "believes," "expects,"
"anticipates," "intends," "estimates," "plan," "will," "may," "look forward,"
"intend," "guidance," "future" or similar expressions are forward-looking
statements. Because these statements reflect Endo's current views,
expectations and beliefs concerning future events, these forward-looking
statements involve risks and uncertainties. Although Endo believe that these
forward-looking statements and information are based upon reasonable
assumptions and expectations, readers should not place undue reliance on them,
or any other forward-looking statements or information in this news release.
Investors should note that many factors, as more fully described in the
documents filed by Endo and Endo Health Solutions Inc. ("EHSI") with
securities regulators in the United States and Canada including under the
caption "Risk Factors" in EHSI's Form 10-K, and Endo's Form 10-Q and Form 8-K
filings, as applicable, with the Securities and Exchange Commission and by
Endo with securities regulators in Canada on the System for Electronic
Document Analysis and Retrieval ("SEDAR") and as otherwise enumerated herein
or therein, could affect Endo's future financial results and could cause
Endo's actual results to differ materially from those expressed in
forward-looking statements contained in EHSI's Annual Report on Form 10-K. The
forward-looking statements in this press release are qualified by these risk
factors. These are factors that, individually or in the aggregate, could cause
Endo's actual results to differ materially from expected and historical
results. Endo does not assume any obligation to publicly update any
forward-looking statements, whether as a result of new information, future
developments or otherwise, except as may be required under applicable
SOURCE Endo International plc
Investors/Media: Blaine Davis, +353-1-669-6635, (484) 216-7158; Investors:
Jonathan Neely, (484) 216-6645; Media: Heather Zoumas-Lubeski, (484) 216-6829
CO: Paladin Labs Inc.
NI: HEA MTC BTC NP
Press spacebar to pause and continue. Press esc to stop.